Capecitabine

Chemical formula: C₁₅H₂₂FN₃O₆ Molecular mass: 359.35 g/mol PubChem compound: 60953

Therapeutic indications

Capecitabine is indicated for:

Gastric cancer - combination treatment with a platinum based regimen

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of first-line treatment of advanced gastric cancer in combination with a platinum based regimen.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

800-1000 mg/m² twice daily for 14 days followed by a 7-day rest period, or 625 mg/m² twice daily when administered continuously

Breast cancer - monotherapy

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1,250 mg/m² twice daily for 14 days followed by a 7-day rest period

Colorectal cancer - monotherapy

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of metastatic colorectal cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1,250 mg/m² twice daily for 14 days followed by a 7-day rest period

Breast cancer - combination therapy with docetaxel

Population group: only adults (18 years old or older)

Capecitabine is indicated in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1,250 mg/m² twice daily for 14 days followed by a 7-day rest period

Colorectal cancer - combination treatment

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of metastatic colorectal cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

800-1000 mg/m² twice daily for 14 days followed by a 7-day rest period, or 625 mg/m² twice daily when administered continuously

Stage III (Dukes' stage C) colon cancer after surgery - monotherapy

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1,250 mg/m² twice daily for 14 days followed by a 7-day rest period, for a total of 6 months

Stage III (Dukes' stage C) colon cancer after surgery - combination treatment

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

800-1000 mg/m² twice daily for 14 days followed by a 7-day rest period, or 625 mg/m² twice daily when administered continuously, for 6 months

Contraindications

Capecitabine is contraindicated in the following cases:

Severe leucopenia, neutropenia, thrombocytopenia

at least one of

Leukopenia
Neutropenia
Thrombocytopenic disorder

Pregnancy

Pregnancy

Lactation

Lactation

Known complete dihydropyrimidine dehydrogenase (DPD) deficiency

Dihydrouracil dehydrogenase (NADP^+^) deficiency

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment (creatinine clearance below 30 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Brivudine

Brivudine

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈